WaferGen Bio-systems, Inc.  

(Public, NASDAQ:WGBS)   Watch this stock  
Find more results for PINK:WGBS
+0.45 (12.33%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.80 - 4.20
52 week 2.95 - 35.00
Open 3.80
Vol / Avg. 109,016.00/177,181.00
Mkt cap 20.63M
P/E     -
Div/yield     -
EPS -43.43
Shares 5.65M
Beta 1.32
Inst. own 62%
Sep 10, 2014
Wafergen Biosystems Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -121.31% -1246.70%
Operating margin -181.73% -881.90%
EBITD margin - -707.41%
Return on average assets -79.71% -155.45%
Return on average equity - -
Employees 28 -
CDP Score - -


7400 Paseo Padre Pkwy
FREMONT, CA 94555-3663
United States - Map
+1-510-6514450 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


WaferGen Bio-systems, Inc. (WBSI) is engaged in the development, manufacture and marketing of laboratory analytical instruments for cell biology, and later started the development of analytical instrumentation for gene expression and genotyping research for the life sciences and pharmaceutical drug discovery industries. WBSI is primarily focused on developing a gene expression and genotyping product, the WaferGen SmartChip System. The Company has first generation SmartChip 5K System, which is a polymerase chain reaction (real-time PCR)2 tool to enable scientists to study thousands of genes simultaneously based on gene specific pathways, potentially to discovery of clinically relevant disease signatures. It also provides in-house gene-expression profiling for sales demonstrations and collaborations using the SmartChip System. In January 2014, the Company announced that it has completed the acquisition of the NGS library preparation business from IntegenX Inc.

Officers and directors

Ivan D. Trifunovich Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Michael P. Henighan Chief Financial Officer
Age: 60
Bio & Compensation  - Reuters
Keith Warner Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Stephen T. Baker Treasurer, Secretary
Age: 56
Bio & Compensation  - Reuters
Joel Stephen Kanter Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
Robert Schueren Director
Age: 52
Bio & Compensation  - Reuters
Raymond Dean Hautamaki Independent Director
Age: 51
Bio & Compensation  - Reuters
Makoto Kaneshiro Independent Director
Age: 55
Bio & Compensation  - Reuters
William McKenzie Independent Director
Age: 62
Bio & Compensation  - Reuters